Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System.
Animals
Antineoplastic Agents
/ pharmacology
Biocompatible Materials
/ chemistry
Cell Death
/ drug effects
Cell Line
Cell Movement
/ drug effects
Clone Cells
Diffusion
Drug Carriers
/ chemistry
Drug Delivery Systems
Ferritins
/ chemistry
Folic Acid
/ chemistry
Horses
Humans
Hydrogen-Ion Concentration
Phenylurea Compounds
/ chemistry
Piperidines
/ chemistry
Protein Kinase Inhibitors
/ pharmacology
Quinazolines
/ chemistry
Quinolines
/ chemistry
Surface Properties
drug delivery
lenvatinib
nanomedicine
vandetanib
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
08
2020
accepted:
07
11
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system. The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities. The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.
Identifiants
pubmed: 33442247
doi: 10.2147/IJN.S275808
pii: 275808
pmc: PMC7797358
doi:
Substances chimiques
Antineoplastic Agents
0
Biocompatible Materials
0
Drug Carriers
0
Phenylurea Compounds
0
Piperidines
0
Protein Kinase Inhibitors
0
Quinazolines
0
Quinolines
0
Ferritins
9007-73-2
Folic Acid
935E97BOY8
lenvatinib
EE083865G2
vandetanib
YO460OQ37K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Informations de copyright
© 2021 Skubalova et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cell Physiol Biochem. 2019;53(5):805-819
pubmed: 31670920
Theranostics. 2020 Jan 1;10(2):687-706
pubmed: 31903145
BMC Cancer. 2019 Jan 8;19(1):41
pubmed: 30621641
J Pharm Sci. 2000 Nov;89(11):1452-64
pubmed: 11015690
Nat Chem Biol. 2012 Nov;8(11):941-8
pubmed: 23001032
Methods Cell Biol. 2019;153:69-92
pubmed: 31395385
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
Ann Oncol. 2004 May;15(5):786-92
pubmed: 15111348
Clin Cancer Res. 2018 Oct 15;24(20):5098-5111
pubmed: 30068707
Adv Healthc Mater. 2015 Jun 24;4(9):1305-10
pubmed: 25973730
ACS Nano. 2013 Aug 27;7(8):6988-96
pubmed: 23829542
Mol Cancer Res. 2009 Oct;7(10):1736-43
pubmed: 19808904
Cancer Cell Int. 2017 May 19;17:56
pubmed: 28533703
J Clin Invest. 2015 May;125(5):1780-9
pubmed: 25932675
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3653-8
pubmed: 12634425
Theranostics. 2021 Jan 1;11(4):1546-1567
pubmed: 33408767
J Pharmacol Exp Ther. 2007 May;321(2):462-8
pubmed: 17289839
Biomacromolecules. 2011 May 9;12(5):1629-40
pubmed: 21446722
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
Sci Rep. 2019 Nov 28;9(1):17755
pubmed: 31780685
Nat Nanotechnol. 2013 Feb;8(2):137-43
pubmed: 23334168
Int J Biol Macromol. 2019 Apr 1;126:1099-1111
pubmed: 30605747
Nanomedicine (Lond). 2014 Jul;9(14):2233-45
pubmed: 25405799
Nanoscale. 2015 Apr 21;7(15):6527-33
pubmed: 25786779
J Control Release. 2020 Sep 10;325:176-190
pubmed: 32619748
J Clin Endocrinol Metab. 2019 Mar 1;104(3):779-784
pubmed: 30383218
Sci Rep. 2017 Nov 24;7(1):16271
pubmed: 29176733
PLoS One. 2017 Apr 18;12(4):e0176015
pubmed: 28419132
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13872-7
pubmed: 16950881
Curr Opin Chem Biol. 2009 Jun;13(3):256-62
pubmed: 19419901
Cancer Res. 2002 Dec 15;62(24):7284-90
pubmed: 12499271
PLoS One. 2018 Jul 31;13(7):e0200302
pubmed: 30063723
ACS Nano. 2018 May 22;12(5):4408-4418
pubmed: 29723464
Oncogene. 2000 Nov 20;19(49):5690-701
pubmed: 11114749
Curr Hematol Malig Rep. 2016 Apr;11(2):71-9
pubmed: 26922746
Cells. 2019 Oct 07;8(10):
pubmed: 31591302
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18182-7
pubmed: 19011101
J Cancer Res Clin Oncol. 2015 May;141(5):769-84
pubmed: 25005786
Am J Physiol Cell Physiol. 2006 Sep;291(3):C445-55
pubmed: 16611735
Cancer Treat Rev. 2016 Jan;42:47-55
pubmed: 26678514
Nature. 2004 Nov 18;432(7015):294-7
pubmed: 15549090
J Am Coll Cardiol. 2015 Sep 8;66(10):1160-78
pubmed: 26337996
Nat Rev Cancer. 2002 Feb;2(2):143-8
pubmed: 12635177
Blood. 2011 Feb 24;117(8):e75-87
pubmed: 20810928
J Colloid Interface Sci. 2019 Mar 1;537:20-27
pubmed: 30415098
Mol Pharmacol. 2004 Jan;65(1):181-95
pubmed: 14722250
Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3673-3683
pubmed: 26980693
Chem Sci. 2017 Dec 18;9(4):790-810
pubmed: 29675145
Cancer Treat Rev. 2015 May;41(5):412-22
pubmed: 25818541
Sci Rep. 2018 Jun 11;8(1):8867
pubmed: 29891921
Toxicology. 2019 May 1;419:40-54
pubmed: 30914192
Biophys J. 2003 Apr;84(4):2256-63
pubmed: 12668434
Drugs. 2019 Apr;79(6):665-674
pubmed: 30993651
Neoplasia. 2003 Nov-Dec;5(6):495-506
pubmed: 14965443
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537
Dalton Trans. 2017 Oct 17;46(40):13690-13694
pubmed: 28971191
ACS Appl Mater Interfaces. 2016 Jun 15;8(23):14430-41
pubmed: 27219717